Cancer is a disease of aging and, as the world's population ages, the number of older
persons with cancer is increasing and will make up a growing share of the oncology …

For several decades, few substantial therapeutic advances have been made for patients
with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen …

Importance It is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic
breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor …

Abstract Background Trastuzumab deruxtecan (T-DXd) has shown durable antitumor activity
in pretreated patients with HER2-positive advanced breast cancer (ABC), but its efficacy has …

Background In the primary analysis of the HER2CLIMB trial, tucatinib added to trastuzumab
and capecitabine significantly improved overall survival (OS) and progression-free survival …

Background Patients with human epidermal growth factor receptor 2 (HER2)–positive
metastatic breast cancer who have disease progression after therapy with multiple HER2 …

PURPOSE Conventional wisdom has rendered patients with brain metastases ineligible for
clinical trials for fear that poor survival could mask the benefit of otherwise promising …

Brain metastases occur commonly in patients with advanced solid malignancies. Yet, less is
known about brain metastases than cancer-related entities of similar incidence. Advances in …

AIDS-Associated Cancers Cancer is a leading cause of death in patients with AIDS. The
incidence of AIDS-defining cancers has been stable owing to highly active antiretroviral …

Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light
of the multitude of recent phase III trials that have failed to meet their primary endpoints …